Johan Wedell-Wedellsborg - Jun 8, 2023 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role: Director
Signature: /s/ Sune Reinholth Nyland, Attorney-in-Fact for Johan Wedell-Wedellsborg
Stock symbol: YMAB
Transactions as of: Jun 8, 2023
Transactions value $: $0
Form type: 4
Date filed: 6/9/2023, 06:04 PM
Previous filing: May 17, 2023
Next filing: Nov 29, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	YMAB	Common Stock	Award	$0	+2.33K		$0.00	2.33K	Jun 8, 2023	Direct	F1
holding	YMAB	Common Stock						4.28M	Jun 8, 2023	By WG Biotech ApS	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	YMAB	Employee Stock Option (right to buy)	Award	$0	+14K		$0.00	14K	Jun 8, 2023	Common stock	14K	$8.13	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of the Issuer's common stock on the vesting date of the RSUs. The RSUs vest in full on the earlier of the first anniversary of the date of grant or the date immediately preceding the date of the Issuer's annual meeting of stockeholders held in 2024, subject to the Reporting Person's continued service to Y-mAbs Therapeutics, Inc. on the vesting date.
F2	Reporting Person is the majority owner of WG Biotech ApS and as such has sole voting and investment power with respect to such shares.
F3	Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.
F4	The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service to Y-mAbs Therapeutics, Inc. on each vesting date and are exercisable immediately upon vesting.